GH Research (GHRS) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GH Research (GHRS) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 60.9% versus a gain of 46.5%. Over five years, GHRS leads with a +23.9% price change compared with +22.2% for TYRA. GH Research is the larger company by market cap ($1.40 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | TYRA |
|---|---|---|
| Share price | $20.45 | $19.97 |
| Market cap | $1.40B | $1.37B |
| 1-day change | -2.90% | -2.06% |
| YTD return | +65.83% | -24.04% |
| 1-year return | +60.89% | +46.52% |
| 5-year return | +23.88% | +22.22% |
| EPS (TTM) | $-0.99 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.44 | $40.65 |
| 52-week low | $12.04 | $13.29 |
| Distance from 52-week high | -34.95% | -50.87% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +109.73% | +137.61% |
| Average volume | 296.90K | 857.13K |
| Shares outstanding | 68.64M | 68.76M |
| Employees | 73 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed TYRA by 14.4 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
GHRS vs TYRA FAQ
Which is bigger, GH Research or Tyra Biosciences?
GH Research (GHRS) is larger, with a market capitalization of $1.40B compared with $1.37B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, GHRS or TYRA?
GHRS returned +60.89% over the past 12 months, compared with +46.52% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.